Archives

Archive for the ‘Human Growth Hormone’ Category

Arginine protein is a conditionally essential amino acid the body uses it in a variety of functioning within the body. Enough of arginine is produced within the body of healthy individuals, Arginine is also obtained from fish, walnuts and a properly balanced diet. The main function of arginine protein is it works as a building block of the body tissues and cells, Arginine protein is also used in dietary supplements for the sports person. Arginine protein is consumed by the most health-conscious consumers, wanting to gain weight and interested in bodybuilding, and also by the childrens for their proper growth and development. Due to the increase in the stress in daily life which might be a cause of chest pain and high blood pressure that could also lead to critical heart dysfunctioning. Arginine Protein is used as a precursor to nitric oxide that maintains the blood pressure along with a healthy cardiovascular system. Along with the health benefits, arginine protein is also used for skin care. In the day to day life, the physical appearance also matters for a lot of young consumers which is growing the market for arginine protein.

Looking for exclusive market insights from business experts?Request a Custom Reporthere.

Increasing Demand for Arginine Protein Due To Increasing Consumer Demand for Various Health Aspects

Nowadays due to the consumption of fast food and improperly balanced diet the growth of childrens are hammered in this situation childrens body is unable to produce enough of arginine required for growth, arginine protein helps in stimulating the human growth hormone that benefits the childrens growth, Not only arginine protein is for childrens but it is also beneficial for young and adult consumers who are interested in muscle building. Due to the intake of excess of oil and junk foodstuff consumers are encountering with cardiovascular defects to avoid this defect nitric oxide plays important role in maintain blood pressure and dilating blood vessels, arginine protein is used as a precursor for nitric oxide that could retain the healthy condition of the heart. Arginine protein is also used in correcting the inborn errors of urea synthesis. In diabetes consumer, arginine protein controls the blood sugar level. Arginine protein regulates the immune and hormone functioning.

Arginine protein is also used in skin care for wound healing and increasing blood flow to cold feet and hands specifically for diabetes customers. Due to increasing stress and hormonal imbalance, there is less supply of blood to the head scalp that might cause loss of hairs, this situation is overwhelmed by the arginine protein that increases the supply of blood to hair root cells that eventually results in hair growth.

Want to know the obstructions to your companys growth in future?Request a brochurehere

Opportunities for Arginine Protein Market Participants

As there are more benefits of arginine protein in the field of healthcare and the skincare there might be increasing demand for arginine protein by the consumers. Manufacturer and market participants should take a chance in doing research and development like introducing new fruit flavors along with the exotic flavors also new participants must focus on making the arginine protein more cost effective and should focus on creative ideas like giving complementary shake bottles, sippers, spoon with proper weight marking so its easy for consumers to consume it with proper dose as suggested, Preexisting manufacturers for arginine protein should focus on attractive packaging along with small packets for trail they should also focus on good marketing strategy that might also uplift the manufacturer market as compared other competitors in the queue.

Visit link:
Arginine Protein Market : Worldwide Industry Analysis and New Market Opportunities Explored 2019 2027 - Online News Guru

Comments Off on Arginine Protein Market : Worldwide Industry Analysis and New Market Opportunities Explored 2019 2027 – Online News Guru
Oct 15th, 2019 | Filed under Human Growth Hormone

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Human Growth Hormone Market by VERTEX MARKET INSIGHTS.

With more number of market data pie chart, tables, figures, and graphs, now the Global Human Growth Hormone Market study is released by VERTEX MARKET INSIGHTS. The comprehensive valuation of the market is presented in the report entailing facts, existing development factors, mindful standpoints, future patterns, and industry-confirmed advertise information forecast up-to 2024. The Human Growth Hormone Market advertise is probably going to develop at a noteworthy CAGR. The principle goal of report is to direct the client comprehend the Market advertise as far as its definition, order, potential, most recent patterns, and the difficulties that the Human Growth Hormone Market advertise is confronting.

Major Key Players of Human Growth Hormone Market:

Novo NordiskPfizerMerck SeronoF. Hoffmann-La RocheFerring PharmaceuticalsGeneScience PharmaceuticalsIpsenLG Life SciencesSandoz InternationalEli LillyAnhui Anke Biotechnology

Get sample Copy of this Human Growth Hormone Market Report at: https://vertexmarketinsights.com/report/32403/world-human-growth-hormone-market-research-report-2024-covering-usa-europe-china-japan-india-south-east-asia-and-etc/#request-sample

The worldwide market for Human Growth Hormone is expected to grow at a CAGR of generally throughout the following five years, will arrive at million US$ in 2024, from million US$ in 2019, as per most recent industry study.

Benefits of Purchasing Human Growth Hormone Market Report:

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Years considered for this report:

Estimated Year: 2019

Historic Year: 2014 to 2018

Forecast Year: 2019 to 2024

Inquire for further detailed information of Human Growth Hormone Market Report at: https://vertexmarketinsights.com/report/32403/world-human-growth-hormone-market-research-report-2024-covering-usa-europe-china-japan-india-south-east-asia-and-etc/#inquiry-before-buying

Maket Segmentation By Types:

PowderSolvent

Maket Segmentation By Applications:

Growth Hormone Deficiency (GHD)Turner SyndromeChronic Renal InsufficiencyPrader Willi SyndromeSmall for Gestational AgeSHOX Deficiency

This exploration report comprises of the worlds vital locale Human Growth Hormone market share, estimate (volume), examples including the thing advantage, esteem, generation, limit, limit utilization, supply, and solicitation and industry improvement rate. Important application areas of Human Growth Hormone are also assessed on the basis of their performance. Market predictions along with the statistical nuances presented in the report render an insightful view of the Human Growth Hormone market. The market study on Global Human Growth Hormone market 2019 report studies present as well as future aspects of the Human Growth Hormone market primarily based upon factors on which the companies compete in the Human Growth Hormone market growth, key trends, and segmentation study.

Highlights of the report: A complete backdrop analysis, which includes an appraisal of the parent showcase Important changes in market elements Market division up to the second or third level Historical, current, and anticipated size of the market from the stance of both worth and volume Reporting and assessment of late industry enhancements Market offers and strategies of key players Emerging forte portions and territorial markets A target evaluation of the direction of the market Recommendations to companies for strengthening their foothold in the market.

Look into Table of Content of Vacuum Capacitor Market Report at : https://vertexmarketinsights.com/report/32403/world-human-growth-hormone-market-research-report-2024-covering-usa-europe-china-japan-india-south-east-asia-and-etc/#table-of-contents

See original here:
Global Human Growth Hormone Market-2019 with high CAGR in Coming Years with Focusing Key players, Types, Application and Forecast to 2024 - Statsflash

Comments Off on Global Human Growth Hormone Market-2019 with high CAGR in Coming Years with Focusing Key players, Types, Application and Forecast to 2024 – Statsflash
Oct 15th, 2019 | Filed under Human Growth Hormone

It is no longer news that several professional sports organizations have banned the use of human growth hormone (HGH). Researchers have found that the decision may be a good one for guarding against undue competitive advantage.

Sprinter

Growth hormone is a naturally-occurring substance in the body. It helps to facilitate growth and development of tissue and organs. For decades, professional athletes have used its synthetic version supposedly to boost muscle growth, faster recovery, and performance, even though this comes with risks.

In research published in the journal Annals of Internal Medicine, scientists from Australia reported that the compound improved recreational athletes ability to sprint. The study was considered the first to confirm that the hormone does indeed boost athletic performance.

This improvement could turn the last place finisher in the Olympic finals into a gold medal winner, said study lead author Dr. Ken Ho, Department of Endocrinology head at St. Vincents Hospital, Sydney.

The study included 96 healthy, recreational athletes aged 18 to 40 years, with the average age being 27. The volunteers were made up of 63 males and 33 females, who were randomly put in an HGH or a placebo group. There were also groups of male volunteers who got testosterone or both HGH and testosterone.

The subjects did not know what they got and the investigators could not tell who received what. Physical and laboratory examinations were used to assess changes in the participants.

At the end of eight weeks, the researchers found that HGH injections improved sprint capacity in the athletes who received them. The ability to sprint on a bicycle improved in male and female subjects who got the hormone by an average of 3.9 percent, compared to those who received a placebo.

We found the enhancement in sprint capacity would correlate to a 0.4 second improvement over 10 seconds in a 100-meter dash, Ho said.

Improvement in sprint capacity was greater in men who received both HGH and testosterone. Those subjects experienced an 8.3 percent increase in capacity, on average.

Boost in sprint capacity faded six weeks after subjects stopped getting treatment.

Scientists also observed that HGH promoted considerable reduction in fat mass, a common reason some people use the substance.

However, it was found that the hormone seemed to have no effect on fitness or ability to jump or pull a weight. The therapy also did not increase muscle mass. This was probably because of the low doses that there used, which still produced side effects all the same.

In our study, we used doses of growth hormone on the low end of what is believed to be abuse in sports, Ho explained. And for that reason, we think that the real effects of growth hormone could be far greater than whats reported in our study.

He noted that higher doses will also increase risk of serious side effects.

Athletes that got growth hormone experienced had more reports of fluid retention and joint pain, compared to those who received a placebo.

Continue reading here:
Human Growth Hormone Proven to Boost Ability to Sprint in Athletes - Gilmore Health News

Comments Off on Human Growth Hormone Proven to Boost Ability to Sprint in Athletes – Gilmore Health News
Oct 13th, 2019 | Filed under Human Growth Hormone

Growth Hormone Therapy Boosts Sensory Function in Patients with Spinal Damage

Researchers have found that human growth hormone (HGH) treatment, combined with physical therapy, can help to speed up recovery in people suffering from spinal damage.

Person With Spinal Injury

It was found in the study, which was presented at the European Congress of Endocrinology held in Portugal, that the substance produced by the pituitary gland helped to significantly enhance sensory function in patients suffering from complete spinal injuries.

Findings from the study could prove useful for development of effective treatments for people with spinal damage.

Although some studies had shown that this substance is needed for restorative and adaptive neuronal processes. But there has been limited research on how it can help to enhance recovery from spinal damage. This is the void that this study by researchers at the Hospital Quiron-Teknon and Guttmann Institute (both in Barcelona) sought to fill.

It is not uncommon for patients to witness dramatic decline in growth hormone levels following a traumatic brain injury, with around 20 percent of people who have such an injury experiencing that. Estimates also have it that between 70 and 80 percent of patients with complete spinal injuries are growth hormone-deficient.

Scientists do not fully know why these patients produce lower amount of the naturally-occurring substance.

In this double-blind, randomized study, researchers examined 18 patients with complete spinal injury. Glucagon test revealed that 13 of these subjects suffered from growth hormone deficiency (GHD), with seven having levels lower than 3 ng/mL.

The patients were given subcutaneous growth hormone injections or placebo for a period of six months. Average age, body mass index (BMI), and waist circumference were comparable for the HGH and placebo groups.

In addition to receiving growth hormone or a placebo, all of the patients underwent physical therapy for two hours a day for the entire duration of the study.

The researchers used standard spinal injury tests of motor and sensory function to evaluate recovery at the third month and again at the sixth month. Subjects treated with growth hormone showed considerable increase in their Spinal Cord Injury Independence (SCIM) III metric, which measured self-care, respiration, and sphincter control, at both three and six months.

Also, those in the treatment group experienced more significant improvement in feeling below the point of their spinal injury after six-month therapy, compared to subjects in the placebo group. This improvement could prove useful for checking pressure ulcers that often result from wheelchair use.

This research is the first human study to look into the relationship between spinal injuries and GHD. It showed that restoring growth hormone levels may help to enhance recovery in spinal damage patients.

A major limitation of this study, however, is that the sample size was small. Larger studies are needed to further explain the findings.

Growth hormone is probably much more important than we think we dont really know the full impact, study lead author Dr. Guillem Cuatrecasas, an endocrinologist at Hospital Quiron-Teknon who led the study, told Medscape Medical News.

He said the therapy could improve upturn in patients with spinal damage at least, in terms of sensory function in the future. According to him, the established concept in medical schools that a broken axon cannot be repaired is wrong.

Further work is needed to look into the distinctions between acute, sub-acute, and chronic spinal damage as well as the best growth hormone doses for treating them.

See more here:
HGH Found to Promote Recovery from Spinal Damage - Gilmore Health News

Comments Off on HGH Found to Promote Recovery from Spinal Damage – Gilmore Health News
Oct 13th, 2019 | Filed under Human Growth Hormone

We are comparing OPKO Health Inc. (NASDAQ:OPK) and Nabriva Therapeutics plc (NASDAQ:NBRV) on their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 shows us OPKO Health Inc. and Nabriva Therapeutics plcs return on assets, net margins and return on equity.

Risk and Volatility

OPKO Health Inc. has a 2.13 beta, while its volatility is 113.00% which is more volatile than Standard & Poors 500. Nabriva Therapeutics plcs 140.00% more volatile than Standard & Poors 500 which is a result of the 2.4 beta.

Liquidity

The Current Ratio of OPKO Health Inc. is 1.1 while its Quick Ratio stands at 1. The Current Ratio of rival Nabriva Therapeutics plc is 5.6 and its Quick Ratio is has 5.6. Nabriva Therapeutics plc is better equipped to clear short and long-term obligations than OPKO Health Inc.

Insider and Institutional Ownership

OPKO Health Inc. and Nabriva Therapeutics plc has shares owned by institutional investors as follows: 26.4% and 49.6%. 5.5% are OPKO Health Inc.s share owned by insiders. Comparatively, Nabriva Therapeutics plc has 0.61% of its share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year OPKO Health Inc. had bearish trend while Nabriva Therapeutics plc had bullish trend.

Summary

On 6 of the 10 factors OPKO Health Inc. beats Nabriva Therapeutics plc.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companys Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companys pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The companys product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Follow this link:
Reviewing OPKO Health Inc. (OPK)'s and Nabriva Therapeutics plc (NASDAQ:NBRV)'s results - MS Wkly

Comments Off on Reviewing OPKO Health Inc. (OPK)’s and Nabriva Therapeutics plc (NASDAQ:NBRV)’s results – MS Wkly
Oct 13th, 2019 | Filed under Human Growth Hormone

This is therefore a comparing of the risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership in Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and OPKO Health Inc. (NASDAQ:OPK). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Demonstrates Apellis Pharmaceuticals Inc. and OPKO Health Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 represents Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and OPKO Health Inc. (NASDAQ:OPK)s return on assets, net margins and return on equity.

Liquidity

Apellis Pharmaceuticals Inc.s Current Ratio and Quick Ratio are 15.2 and 15.2 respectively. The Current Ratio and Quick Ratio of its competitor OPKO Health Inc. are 1.1 and 1 respectively. Apellis Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to OPKO Health Inc.

Institutional & Insider Ownership

Apellis Pharmaceuticals Inc. and OPKO Health Inc. has shares owned by institutional investors as follows: 66.1% and 26.4%. Insiders owned roughly 1.6% of Apellis Pharmaceuticals Inc.s shares. Competitively, 5.5% are OPKO Health Inc.s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Apellis Pharmaceuticals Inc. had bullish trend while OPKO Health Inc. had bearish trend.

Summary

OPKO Health Inc. beats on 6 of the 10 factors Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companys Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companys pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Originally posted here:
Contrasting of Apellis Pharmaceuticals Inc. (APLS) and OPKO Health Inc. (NASDAQ:OPK) - MS Wkly

Comments Off on Contrasting of Apellis Pharmaceuticals Inc. (APLS) and OPKO Health Inc. (NASDAQ:OPK) – MS Wkly
Oct 13th, 2019 | Filed under Human Growth Hormone

Both Trevena Inc. (NASDAQ:TRVN) and Pfenex Inc. (NYSEAMERICAN:PFNX) are each others competitor in the Biotechnology industry. Thus the contrast of their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation and Earnings

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Trevena Inc. and Pfenex Inc.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Trevena Inc. and Pfenex Inc.

Volatility and Risk

Trevena Inc.s current beta is 2.39 and it happens to be 139.00% more volatile than S&P 500. Pfenex Inc.s 129.00% more volatile than S&P 500 which is a result of the 2.29 beta.

Liquidity

The Current Ratio and Quick Ratio of Trevena Inc. are 3.6 and 3.6 respectively. Its competitor Pfenex Inc.s Current Ratio is 5 and its Quick Ratio is 5. Pfenex Inc. can pay off short and long-term obligations better than Trevena Inc.

Analyst Recommendations

Trevena Inc. and Pfenex Inc. Ratings and Recommendations are available on the next table.

$3.5 is Trevena Inc.s consensus target price while its potential upside is 257.14%.

Insider & Institutional Ownership

Institutional investors owned 32.2% of Trevena Inc. shares and 83.6% of Pfenex Inc. shares. Insiders owned 1% of Trevena Inc. shares. Comparatively, 2.14% are Pfenex Inc.s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Trevena Inc.s stock price has bigger growth than Pfenex Inc.

Summary

On 7 of the 10 factors Trevena Inc. beats Pfenex Inc.

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include oliceridine injection, a -receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. Trevena, Inc. was founded in 2007 and is headquartered in King of Prussia, Pennsylvania.

Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial. The company also engages in developing a pipeline of additional biosimilar candidates, including PF529, a biosimilar candidate to Neulasta; PF688, a biosimilar candidate to Cimzia; PF530, a biosimilar candidate to Betaseron; PF690, a biosimilar candidate to the reference product Oncaspar; PF444-human growth hormone, a biosimilar candidate to Genotropin; and PF688-certolizumab-pegol, a biosimilar candidate to Cimzia. It has collaboration agreements with Hospira, Inc. and Jazz Pharmaceuticals Ireland Limited. Pfenex Inc. is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See more here:
Reviewing Trevena Inc. (TRVN)'s and Pfenex Inc. (NYSEAMERICAN:PFNX)'s results - MS Wkly

Comments Off on Reviewing Trevena Inc. (TRVN)’s and Pfenex Inc. (NYSEAMERICAN:PFNX)’s results – MS Wkly
Oct 13th, 2019 | Filed under Human Growth Hormone

The research study, titled Global Human Growth Hormone (hGH) Market Status and Forecast 2019-2026 offers a complete evaluation of this market, covering market size, share, trends, gross margin, opportunities, challenges and risks factors associated to Human Growth Hormone (hGH) market. The report notably highlights the growth boosters, obstructions, changing competitive aspects and future prospects of this market. It categorizes the industry by top players, key region, product type, and application. It explores the most prominent market trends and the present and previous performance of the market in order to determine its status in the near future. The report then analyzes the growth rate, future trends, sales channels, and distributors. Its an enlarging field for top market players functioning in the market to compete with each other.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketresearchplace.com/report-detail/135917/request-sample

The report has collected the data dependent on market structures, high-quality insights, advertises models, and other such factors. It covers the market study and projection on a territorial along with worldwide point. Our researchers have also estimated and large sales and income creation of this specific market.Portfolio analysis given in this market will help users understand the product mix of leading companies in the Human Growth Hormone (hGH) market.

This report focuses on some of the most prominent key vendors in this market, with revenue production, sales, gross margin, and market share for each manufacturer, covering: Eli Lilly and Company, Ferring Holding SA, Genentech, Merck & Co., Novo Nordisk, Pfizer, Sandoz International GmbH, Ipsen,

Applications segment analysis: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Others,

Product segment analysis: Recombinant Human Growth Hormone (rhGH), Human Growth Hormone (rhGH),

The report further presents all-inclusive knowledge of raw materials suppliers, manufacturing cost, capacity, production, profit margin, and capacity utilization rate. Important regions examined in the global market include; Asia-Pacific (China, Southeast Asia, India, Japan, Korea, Western Asia), Europe (Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland), North America (United States, Canada, Mexico), Middle East & Africa (GCC, North Africa, South Africa), South America (Brazil, Argentina, Columbia, Chile, Peru)

This report highlights market dynamics involving the factors impelling the present market scenario as well as growth opportunities of the market in the years to come. Market segmentation analysis was conducted through qualitative and quantitative research, demonstrating the impact of economic and non-economic aspects. Comprehensive company profiles section provides the product offerings, key financial information, business overview, and business strategy. The report additionally delivers an estimate based on the cutting edge business developments and logical procedures.

ACCESS FULL REPORT: https://www.marketresearchplace.com/report/global-human-growth-hormone-hgh-market-status-and-135917.html

Moreover, the tables and figures used in this report will help the reader analyze the worldwide market. It offers direction for companies operating in the market to decide their business plans and achieve business targets in the market. With this report, you will get a detailed understanding of the Human Growth Hormone (hGH) market forces and how those can be exploited to create future opportunities. A short outline of the dealers, distributors, and suppliers has also been covered further. Additionally, it provides sales channel, analysis findings, and results.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketresearchplace.com), who will ensure that you get a report that suits your needs.

Excerpt from:
Human Growth Hormone (hGH) Market Analysis of Major Segments and Future Opportunity Assessment 2019-2026 - The Ukiah Post

Comments Off on Human Growth Hormone (hGH) Market Analysis of Major Segments and Future Opportunity Assessment 2019-2026 – The Ukiah Post
Oct 10th, 2019 | Filed under Human Growth Hormone

The UK health service has well over a decades experience of dealing with biosimilars, but the NHS acknowledges that it has yet to make the most of these drugs.

That was certainly one of the messages from a state of the biosimilar nation event I attended over the summer in London, and its not a surprising one.

The first European biosimilar approval in 2006 for a version of a human growth hormone was, to some extent, a false dawn for the sector, in as much as it didnt pique widespread financial interest from healthcare stakeholders.

That only came more recently, as patent expiries for the blockbuster anti-TNF class of arthritis drugs approached. Now that the likes of Remicade (infliximab), Enbrel (etanercept) and, most importantly, Humira (adalimumab) have to compete with biosimilar versions, the NHS is grappling with how to make the most of this opportunity.

Thus, it made sense for Anne Marie Morris MP, who is also chair of the All-Party Parliamentary Group on Access to Medicines and Medical Devices, to outline the huge opportunity that biologics present.

Biosimilars are clearly a new and big issue for us, she said, introducing Westminster Health Forms Biosimilars in the NHS Commissioning, Development and Engagement with Clinicians and Patients event in London.

We need to ensure that there is access to NHS patients for these biosimilars and we need to be an attractive market so that biosimilars are developed here and not, dare I say, in the USA. But we also need to take patients with us, because these are different medicines, she said.

Something like adalimumab requires a whole system approach to drive the change that we requireSuzy Heafield

The place for biosimilars within the NHS

Exactly how the NHS is working to ensure biosimilar access was comprehensively explained by Suzy Heafield, a commissioning pharmacist who works for NHS England and NHS Improvement as head of medicines value and sits within its relatively new Commercial Medicines Directorate.

Prior to that she was a clinical pharmacist in Nottingham and then a commissioning pharmacist working for Clinical Commissioning Groups (CCGs) and the Primary Care Trusts (PCTs) that preceded them.

She noted that, from a commercial point of view, there are two key recent policy documents that drive NHS England and NHS Improvements commercial policy, including its approach to biosimilars. One is the NHS Long-Term Plan and the other the Voluntary Scheme for Branded Medicines Pricing and Access.

The Commercial Medicines Directorates mission was, she said, commercially-focused, but clinically-led.

So, our commercial activity is fundamental to supporting patient access. Our priority is to allow access to the latest innovative and most clinically-effective new healthcare treatments and solutions. But at the same time, we want to make sure we secure maximum value for the NHS and taxpayers from its ever-growing spend on medicines and other healthcare solutions.

And there are big numbers at stake. Last October Humira (adalimumab), still the worlds biggest-selling drug, came off patent in Europe, after which the NHS struck an historic biosimilar deal that represented the biggest saving in its history from a single drug negotiation.

Looking further ahead, NHS England envisages savings as a whole from biosimilars of some 400 500 million per year by 2021, if it can increase uptake of best value biologic medicines.

This would give the health service headroom to be able to fund new treatments and to improve access to patients, Heafield said, adding that NHS England is eyeing up being able to use some of the money saved for new investments into improving care pathways.

To do this, the Commercial Medicines Directorate is running the Best Value Biologics Project to enable appropriate use and uptake whether of the originator product or a biosimilar version.

She explained: Where a best value biologic isnt the originator, were looking at switching and how we can enable switching. The introduction of biosimilars drives greater competition and releases cost-efficiencies through competition, and it also supports increased access to biological medicines.

So, we may be looking at access to biologics at an earlier stage in the treatment pathway. Or we may be looking at access to new innovative medicines.

As examples of some of the newer, expensive treatments coming through that would need to be funded somehow, Heafield cited CAR-T and gene therapies.

NHS biosimilar uptake

The NHS has a steep uptake target for adoption of the best value biologic product, aiming for 80% of patients to be using it within one year of a biosimilar version first becoming available.

It didnt achieve that with Remicade and Enbrel, which were the first two anti-TNF biologics to face competition. In fact, Remicade took 28 months to reach the 80% target, and after 12 months Enbrel had only reached 50% of eligible patients.

That changed with the next two biosimilars to come online, which were versions of the cancer drugs MabThera (rituximab) and Herceptin (trastuzumab). This time around incentives were put in place under a Commissioning for Quality and Innovation (CQUIN) framework and there was closer working with the Cancer Vanguard and NHS Improvement.

We saw a massive change in the uptake of rituximab and trastuzumab with rituximab we achieved 80% uptake at month ten after launch, and trastuzumab at month eight, Heafield said.

After MabThera and Herceptin it was all eyes on Humira for the NHS and uptake of the best value biologic versions of the arthritis drug was heading towards 67% at month seven, but it still faces regional variation in uptake.

It just shows that something like adalimumab requires a whole system approach to drive the change that we required, and it has been successful. But obviously we wont be resting on our laurels, said Heafield.

One of the next priorities for biosimilars in the future is to plan for the next Humira tender, because the initial NHS agreement was only signed for a year so will in theory expire in December. But Heafield and the NHS Commercial Medicines Directorate also have plans for a more nuanced approach to the use of biosimilars.

We need to work with clinicians and patient groups to determine if, and when, we should look at biosimilar-to-biosimilar switching. Up to now all weve been saying is originator-to-biosimilar. Theres now evidence emerging around biosimilar-to-biosimilar, but again this cant be a done to, it has to be a done with, and at the appropriate time, she concluded.

The rest is here:
Biosimilars in the UK: where are we now and where does the NHS want to go? - - pharmaphorum

Comments Off on Biosimilars in the UK: where are we now and where does the NHS want to go? – – pharmaphorum
Oct 10th, 2019 | Filed under Human Growth Hormone

In this report, the Global Recombinant Human Growth Hormone market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Global Recombinant Human Growth Hormone market has been broken down by major regions, with complete market estimates on the basis of products/applications on a regional basis.

Browse full research report at https://www.crystalmarketreport.com/global-recombinant-human-growth-hormone-market-report-history-and-forecast-2014-2025-breakdown-data-by-manufacturers-key-regions-types-and-application

Summary

Recombinant Human Growth Hormone (HGH) is a bioactive protein intended for use in cell culture applications. HGH is a hormone with multiple effects. HGH is a pleiotropic molecule that binds the GH receptor. Recombinant Human Growth Hormone (HGH) is one of our more than 250 available Gibco recombinant proteins.

The global Recombinant Human Growth Hormone market was xx million US$ in 2018 and is expected to xx million US$ by the end of 2025, growing at a CAGR of xx% between 2019 and 2025.

This report studies the Recombinant Human Growth Hormone market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Recombinant Human Growth Hormone in these regions, from 2014 to 2025, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include

Novo Nordisk

Pfizer

Eli Lilly

Merck Serono

F.Hoffmann-La Roche

Ferring Pharmaceuticals

GeneScience Pharmaceuticals

Ipsen

LG Life Sciences

Sandoz International

Anhui Anke Biotechnology

BioPartners

By the product type, the market is primarily split into

Powder

Solvent

By the end users/application, this report covers the following segments

Growth Hormone Deficiency (GHD)

Turner Syndrome

Chronic Renal Insufficiency

Prader Willi Syndrome

Small for Gestational Age

SHOX Deficiency

Others

We can also provide the customized separate regional or country-level reports, for the following regions:

North America

United States

Canada

Mexico

Asia-Pacific

China

Japan

South Korea

India

Australia

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Europe

Germany

France

UK

Italy

Russia

Central & South America

Brazil

Middle East & Africa

Turkey

GCC Countries

Egypt

South Africa

The study objectives of this report are:

To study and analyze the global Recombinant Human Growth Hormone market size (value & volume) by company, key regions/countries, products and application, history data from 2014 to 2018, and forecast to 2025.

To understand the structure of Recombinant Human Growth Hormone market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Recombinant Human Growth Hormone manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Recombinant Human Growth Hormone with respect to individual growth trends, future prospects, and their contribution to the total market.

To project the value and volume of Recombinant Human Growth Hormone submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Recombinant Human Growth Hormone are as follows:

History Year: 2014-2018

Base Year: 2018

Estimated Year: 2019

Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million USD) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Recombinant Human Growth Hormone market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders

Raw material suppliers

Distributors/traders/wholesalers/suppliers

Regulatory bodies, including government agencies and NGO

Commercial research & development (R&D) institutions

Importers and exporters

Government organizations, research organizations, and consulting firms

Trade associations and industry bodies

End-use industries

Available Customizations

With the given market data, QYResearch offers customizations according to the companys specific needs. The following customization options are available for the report:

Further breakdown of Recombinant Human Growth Hormone market on basis of the key contributing countries.

Detailed analysis and profiling of additional market players.

Browse full research report at https://www.crystalmarketreport.com/global-recombinant-human-growth-hormone-market-report-history-and-forecast-2014-2025-breakdown-data-by-manufacturers-key-regions-types-and-application

Reasons to Buy This Research Report

About Crystal Market Reports

Crystal Market Reports is a distributor of market research spanning 160 industries. Our extensive database consists of over 400,000 quality publications sourced from 400 plus publishers, this puts our research specialists in the unique position of been able to offer truly unbiased advice on what research provides the most valuable insights.

Contact Info.:-

Go here to see the original:
Global Recombinant Human Growth Hormone Market Report, History and Forecast 2014-2025, Breakdown Data by Manufacturers, Key Regions, Types and...

Comments Off on Global Recombinant Human Growth Hormone Market Report, History and Forecast 2014-2025, Breakdown Data by Manufacturers, Key Regions, Types and…
Oct 10th, 2019 | Filed under Human Growth Hormone